Other Peripheral Nerve DiseasePhase 4NCT02691442
Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery
A Phase 4 study testing Ropivacaine 0.75%, Levobupivacaine 0.5% and Levobupivacaine 0.5% + epinephrin 1/200000 in people with Other Peripheral Nerve Disease, run by University Hospital, Antwerp.
Trial summary
Several reports have compared the duration of action of levobupivacaine and ropivacaine as local anesthetic. The most widely used method for sensory function evaluation is though means of a pinprick test. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Other Peripheral Nerve Disease
- What is being tested?
- Ropivacaine 0.75%, Levobupivacaine 0.5% and Levobupivacaine 0.5% + epinephrin 1/200000
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- Dec 2010to Apr 2016
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American Society of Anesthesia class I or II
- Scheduled for shoulder surgery
Who cannot join
- Mental retardation
- Allergy for local anesthetics
- NSAID intolerance or contraindicated
- Diabetes mellitus
- Chronic use of pain killers
About this study
Official title: Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia
Several reports have compared the duration of action of levobupivacaine and ropivacaine as local anesthetic. The most widely used method for sensory function evaluation is though means of a pinprick test. The investigators want to use the novel method of Quantitative Sensory Testing to better evaluate the anesthetic activity. This method used hot and cold sensation to assess small nerve fiber function. The investigators will assess the duration of action of different drugs when used in an inter scalene nerve block in patients scheduled for shoulder surgery.
Read the detailed description
This study aims to compare the length of the analgesic effect of different local anesthesic solutions, used in an interscalene nerve block. This will be objectified by measuring the changes in small nerve functioning, using quantative sensory testing. Based on the results of a previous study, the investigators reduce the dose of the administered local anesthetic, expecting a similar length of action using these smaller doses.
- Conditions
- Other Peripheral Nerve Disease
- Being tested
- Ropivacaine 0.75%, Levobupivacaine 0.5%, Levobupivacaine 0.5% + epinephrin 1/200000
- Keywords
- Peripheral nerve block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ropivacaine 0.75%Drug
Also called Naropin
The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
Levobupivacaine 0.5%Drug
Also called Chirocaine
The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
Levobupivacaine 0.5% + epinephrin 1/200000Drug
Also called Chirocaine
The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
| Study group | Role | What they receive |
|---|---|---|
| Ropivacaine 0.75% | Active comparator | The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space Receives: Drug: Ropivacaine 0.75% |
| Levobupivacaine 0.5% | Active comparator | The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space Receives: Drug: Levobupivacaine 0.5% |
| Levobupivacaine 0.5% + epinephrin | Active comparator | The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space Receives: Drug: Levobupivacaine 0.5% + epinephrin 1/200000 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of nerve block measured in longitudinally recorded significant changes in sensory thresholds using quantitative sensory testing
Length of difference in cold and heat pain and sensation measured with quantitative sensory testing
Measured: 24 hours after intervention
Secondary outcomes (3)
Need for rescue drugs, as requested by the patient after surgery
Measured: 24 hours after intervention
Motor activity block, longitudinally recorded inability to move the blocked limb
Measured: 24 hours after intervention
Intensity of nerve block, recorded as maximal changes in sensory thresholds using quantitative sensory testing
The difference in threshold of cold and heat pain and sensation measured with quantitative sensory testing
Measured: 24 hours after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2016 (estimated)
- Study startDec 2010
- Primary completionDec 2015
- Study completionApr 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Other Peripheral Nerve DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, AntwerpThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tom Schepens, MD, University Hospital, Antwerp
- Investigators
- Luc Serieus, MD, Study chair, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02691442
- Sponsor's protocol ID
- EC 10/45/315
- Status last verified
- Aug 2016
- First submitted
- 1 Feb 2016
- Last updated
- 15 Aug 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Sermeus LA, Schepens T, Hans GH, Morrison SG, Wouters K, Breebaart MB, Smitz CJ, Vercauteren MP. A low dose of three local anesthetic solutions for interscalene blockade tested by thermal quantitative sensory testing: a randomized controlled trial. J Clin Monit Comput. 2019 Apr;33(2):307-316. doi: 10.1007/s10877-018-0150-3. Epub 2018 May 3.
PubMed 29725795
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia
- ClinicalTrials.gov ID
- NCT02691442
- Acronym / sponsor ID
- EC 10/45/315
- Conditions
- Other Peripheral Nerve Disease
- Keywords
- Peripheral nerve block
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Study start
- Dec 2010
- Primary completion
- Dec 2015 (actual)
- Study completion
- Apr 2016 (actual)
- First posted
- 25 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Several reports have compared the duration of action of levobupivacaine and ropivacaine as local anesthetic. The most widely used method for sensory function evaluation is though means of a pinprick test. The investigators want to use the novel method of Quantitative Sensory Testing to better evaluate the anesthetic activity. This method used hot and cold sensation to assess small nerve fiber function. The investigators will assess the duration of action of different drugs when used in an inter scalene nerve block in patients scheduled for shoulder surgery.
Detailed description
This study aims to compare the length of the analgesic effect of different local anesthesic solutions, used in an interscalene nerve block. This will be objectified by measuring the changes in small nerve functioning, using quantative sensory testing. Based on the results of a previous study, the investigators reduce the dose of the administered local anesthetic, expecting a similar length of action using these smaller doses.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Ropivacaine 0.75% | Active comparator | Drug: Ropivacaine 0.75%The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space |
| Levobupivacaine 0.5% | Active comparator | Drug: Levobupivacaine 0.5%The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space |
| Levobupivacaine 0.5% + epinephrin | Active comparator | Drug: Levobupivacaine 0.5% + epinephrin 1/200000The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesia class I or II
- Scheduled for shoulder surgery
Key exclusion criteria (5 listed)
- Mental retardation
- Allergy for local anesthetics
- NSAID intolerance or contraindicated
- Diabetes mellitus
- Chronic use of pain killers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ropivacaine 0.75%Also: NaropinThe investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block | Drug | Ropivacaine 0.75% |
| Levobupivacaine 0.5%Also: ChirocaineThe investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block | Drug | Levobupivacaine 0.5% |
| Levobupivacaine 0.5% + epinephrin 1/200000Also: ChirocaineThe investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block | Drug | Levobupivacaine 0.5% + epinephrin |
Primary outcome
Length of nerve block measured in longitudinally recorded significant changes in sensory thresholds using quantitative sensory testing
Time frame: 24 hours after intervention
Length of difference in cold and heat pain and sensation measured with quantitative sensory testing
3 secondary outcomes
Need for rescue drugs, as requested by the patient after surgery
Time frame: 24 hours after intervention
Motor activity block, longitudinally recorded inability to move the blocked limb
Time frame: 24 hours after intervention
Intensity of nerve block, recorded as maximal changes in sensory thresholds using quantitative sensory testing
Time frame: 24 hours after intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2016.
- Derived from this study: PubMed 29725795Sermeus LA, Schepens T, Hans GH, Morrison SG, Wouters K, Breebaart MB, Smitz CJ, Vercauteren MP. A low dose of three local anesthetic solutions for interscalene blockade tested by thermal quantitative sensory testing: a randomized controlled trial. J Clin Monit Comput. 2019 Apr;33(2):307-316. doi: 10.1007/s10877-018-0150-3. Epub 2018 May 3.
- Individual participant dataSharing planned: No
Related trials for Other Peripheral Nerve Disease
RecruitingObservational study
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Charcot-Marie-Tooth, CMT1A
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Wilms Tumor, Rhabdoid Tumor
Recruiting
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
Neurofibromatosis Type 1
RecruitingPhase 1/2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Solid Tumors, Advanced Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luc Serieus, MD study chair
University Hospital, Antwerp
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ropivacaine 0.75%, Levobupivacaine 0.5% and Levobupivacaine 0.5% + epinephrin 1/200000 in people with Other Peripheral Nerve Disease, run by University Hospital, Antwerp.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of nerve block measured in longitudinally recorded significant changes in sensory thresholds using quantitative sensory testing (time frame: 24 hours after intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02691442, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2016.